Lantern Pharma's LP-184 Gains the US FDA’s Fast-Track Designation to Treat TNBC
Shots:
- This designation is based on anti-tumor activity in 10 TNBC PDX models & LP-184 also shown consistent efficacy in both PARPi-resistant & PARPi-sensitive tumors, achieving complete tumor regression (107-141% tumor growth inhibition).
- This is a 2nd FTD designation in 2024, i.e., Lantern received FTD for Gliobastoma in October. Although data was presented at the SABCS 2022
- LP-184 is in a P-Ia study evaluating safety & tolerability for various solid tumor types, incl. TNBC. LP-184 was developed using Lantern's RADR AI platform to identify patient populations & cancer subtypes that may respond to the treatment
Ref: BusinessWire | Image: Lantern Pharma
Related News:- Lantern Pharma’s LP-184 Gains the US FDA’s Fast-Track Designation for Treating Glioblastoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
